Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

John T, Kohler D, Pintilie M, Yanagawa N, Pham NA, Li M, Panchal D, Hui F, Meng F, Shepherd FA, Tsao MS.

Clin Cancer Res. 2011 Jan 1;17(1):134-41. doi: 10.1158/1078-0432.CCR-10-2224. Epub 2010 Nov 16.

2.

[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].

Han C, Zou H, Ma J, Zhou Y, Zhao J.

Zhongguo Fei Ai Za Zhi. 2010 Sep;13(9):882-91. doi: 10.3779/j.issn.1009-3419.2010.09.09. Review. Chinese.

3.

KRAS mutations in non-small cell lung cancer.

Riely GJ, Marks J, Pao W.

Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5. doi: 10.1513/pats.200809-107LC. Review.

PMID:
19349489
4.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461
5.

Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?

Aggarwal C, Somaiah N, Simon GR.

J Natl Compr Canc Netw. 2010 Jul;8(7):822-32. Review.

PMID:
20679541
6.

Patient-derived tumour xenografts as models for oncology drug development.

Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG.

Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50. doi: 10.1038/nrclinonc.2012.61. Review.

7.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Gazdar AF, Hirsch FR, Minna JD.

J Thorac Oncol. 2016 Mar;11(3):287-99. doi: 10.1016/j.jtho.2015.10.009. Epub 2015 Dec 24. Review.

8.

Comparative pathobiology of environmentally induced lung cancers in humans and rodents.

Pandiri A.

Toxicol Pathol. 2015 Jan;43(1):107-14. doi: 10.1177/0192623314556516. Epub 2014 Oct 27. Review.

9.

Patient-derived xenograft models in gynecologic malignancies.

Scott CL, Mackay HJ, Haluska P Jr.

Am Soc Clin Oncol Educ Book. 2014:e258-66. doi: 10.14694/EdBook_AM.2014.34.e258. Review.

10.

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.

Wainwright DA, Horbinski CM, Hashizume R, James CD.

Neurotherapeutics. 2017 Apr;14(2):385-392. doi: 10.1007/s13311-017-0523-1. Review.

PMID:
28321824
11.

Growth rate analysis and efficient experimental design for tumor xenograft studies.

Hather G, Liu R, Bandi S, Mettetal J, Manfredi M, Shyu WC, Donelan J, Chakravarty A.

Cancer Inform. 2014 Dec 9;13(Suppl 4):65-72. doi: 10.4137/CIN.S13974. eCollection 2014. Review.

Supplemental Content

Support Center